Skip to content

Gossamer Bio, Inc.

GOSS· NasdaqCore metricsCIK 1728117

Pharmaceutical preparations551 peers

Last sale
Nov 12, 2026 · -4.39%
Market cap
$67.95M
6.12M shares
Filings
490
$38.43M
Q3 2026−57.7% FY25 yoy
-$48.07M
Q3 2026N/M FY25 yoy
$7.20M
Q3 2026N/M FY25 yoy
-$107.72M
Q3 2026derivedN/M FY25 yoy
-$7.36
Q3 2026N/M FY25 yoy
$51.19M
Q3 2026−18.1% FY25 yoy
$67.95M
—
0.9×
—
-229.63%
—

Twelve months to Sep 30, 2026 · derived

Price

$11.1194.63%$195.69past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$48.47MFY 2025
$114.70M0FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$48,471,000reported
FY 20242024-12-31$114,701,000reported
FY 20232023-12-31$0reported
FY 20222022-12-31$0reported

Segments

Products
Revenue by Products, FY2022 to FY2025FY2022FY2023FY2024Revenue from contracts with collaborators · FY2024 · $24.02MRevenue from sale of licenses · FY2024 · $90.68MFY2025Revenue from contracts with collaborators · FY2025 · $48.47M
LineFY2025ShareChange
Revenue from contracts with collaborators$48.47M100%+101.8%
Revenue from sale of licenses$0.00—−100.0%
Total$48.47M

From the 10-K filed Mar 17, 2026GOSS

Pharmaceutical preparations

Gossamer Bio, Inc. is the 129th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Gossamer Bio, Inc. · CIK 1728117 · Engraved from SEC EDGAR